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Background
Common Variable Immunodeficiency (CVID) is character-
ized by reduced serum levels of immunoglobulins (Ig) and
its treatment requires regular infusion of intravenous immu-
noglobulin (IVIG). Eventually CVID female patients will
reach reproductive age and it is known that maternofetal
transplacental transport of antibodies is important to protect
the child in the first months of life. The IgG present in fetal
circulation comes from the mother after being actively
transfered across the placenta. Although the required recep-
tors for the transfer are expressed early on, most of it occurs
in the third trimester of pregnancy and therefore this is the
most important period for newborn protection. Transpla-
cental transport of IgG is similar in pregnant women with
and without CVID(Costa-Carvalho et al.).To this date, it is
not established how the IVIG infusion should be conducted
in order to maintain adequate IgG levels for the pregnant
woman with CVID and her newborn.
Objectives
To evaluate IVIG dose and serum levels of IgG during
pregnancy in CVID patients.
Methods
Retrospective analysis of chart data of pregnant CVID
patients. All patients received IVIG every 4 weeks. Data on
weight gain, IVIG doses received and their IgG serum
levels obtained immediately before the monthly infusion,
data on infectious episodes reported during visits, delivery
and the newborns were collected.
Results
Eight pregnancies in 6 patients were studied in CVID
patients aged 20-37 years, all being either the first or the
second pregnancy. They were using IVIG for an average
of 3 years (± 2 years). All patients had pulmonary
abnormalities as the main morbidity factor. Weight var-
ied from a 2.2kg weight loss to a 11.6kg weight gain
(mean 7.5kg ± 4.9kg). They received a mean IVIG dose
of 648mg/kg/dose monthly. There was no difference
between IgG levels before and during the pregnancies.
There were an average of 1.5 infectious episodes reported
during visits per pregnancy that required antibiotic use.
All babies were full term, all had an average birth weight
of 3,254g(±305g) and were discharged home 72 h after
delivery.
Conclusions
IVIG dose adjustment during pregnancy in CVID
patients successfully maintained IgG levels without any
disease aggravating factors.
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